This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Horizon Pharma plc
Drug Names(s): sodium benzoate/sodium phenylacetate
Description: Ammonul is the combination of 10% sodium phenylacetate and 10% sodium benzoate. It works by works by scavenging ammonia through a reaction with glycine (in the case of benzoate) or glutamine (in the case of phenylacetate) to form water-soluble and renally excretable compounds (benzoylglycine or hippurate and phenylacetylglutamine, respectively) that eliminate ammonia through the urine. It bypasses the urea cycle and requires intact renal function for elimination of ammonia.
Medicis(Ucyclyd) and Hyperion
In August 2007, Medicis and Hyperion Therapeutics announced a strategic collaboration between Hyperion and Medicis' subsidiary, Ucyclyd Pharma, pursuant to which Hyperion will be responsible for the ongoing research and development of a compound referred to as GT4P for the treatment of Urea Cycle Disorder (UCD), Hepatic Encephalopathies (HE) and other indications, and additional indications for Ammonul. Hyperion also will co-promote Ucyclyd's existing on-market products, Ammonul and Buphenyl, for the treatment of UCD.
Pursuant to an amended and restated collaboration agreement, with Ucyclyd, entered into in March 2012, Hyperion has an option to purchase all of Ucyclyd's worldwide rights in BUPHENYL and AMMONUL (sodium phenylacetate and sodium benzoate) injection 10%/10%, for an upfront payment of $22.0 million, plus subsequent milestone and royalty payments.
To fund this upfront payment, Hyperion may choose to draw on a loan...See full deal structure in Biomedtracker
Additional information available to subscribers only: